When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. National Bleeding Disorders Foundation - Wikipedia

   en.wikipedia.org/wiki/National_Bleeding...

   The National Bleeding Disorders Foundation (NBDF) is a United States patient advocacy organization for the care and treatment of inheritable blood and bleeding disorders such as hemophilia and von Willebrand disease. Founded in 1948, NBDF, then known as the National Hemophilia Foundation, helps secure funding for treatment centers and develops ...

3. Acquired haemophilia - Wikipedia

   en.wikipedia.org/wiki/Acquired_haemophilia

   Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII.These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.

4. Pfizer's gene therapy cuts hemophilia A bleeding rate ... - AOL

   www.aol.com/news/pfizers-hemophilia-gene-therapy...

   If approved, Pfizer's hemophilia A gene therapy will compete with BioMarin Pharmaceutical's one-time treatment Roctavian, which was approved in the U.S. last year and is priced at $2.9 million.

5. FDA Approves Pfizer's Second Hemophilia Drug With Six Months

   www.aol.com/fda-approves-pfizers-second...

   Hemophilia is a family of rare genetic blood diseases caused by a clotting factor deficiency (FVIII in hemophilia A, FIX in hemophilia B), impacting more than 800,000 people globally.

6. Contaminated haemophilia blood products - Wikipedia

   en.wikipedia.org/wiki/Contaminated_haemophilia...

   Contaminated hemophilia blood products were a serious public health problem in the late 1970s up to 1985. [citation needed] Hemophilia A causes a deficiency in Factor VIII, a protein required for blood clotting. Factor VIII injections are a common treatment to prevent or stop bleeding in people with hemophilia A. [1]

7. Alnylam Files Clinical Trial Application to Initiate a Phase ...

   www.aol.com/news/2013-01-03-alnylam-files...

   Notably, GalNAc-siRNAs are being employed in Alnylam's ALN-TTRsc and ALN-AT3 RNAi therapeutic programs for the treatment of transthyretin-mediated amyloidosis (ATTR) and hemophilia and rare ...